{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:43:32Z","timestamp":1759693412277,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Edanz Group"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.mehy.2019.03.030","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T18:44:02Z","timestamp":1553712242000},"page":"23-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Possible participation of colloid antigen 2 and abhormone (IgG with hormone activity) for the etiology of Graves\u2019 disease"],"prefix":"10.1016","volume":"127","author":[{"given":"Yukio","family":"Ochi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2019.03.030_b0005","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.mehy.2012.03.006","article-title":"A novel hypothesis for the etiology of Graves' disease: TSAb may be thyroid stimulating animal IgG-like hormone and TBAb my be the precursor of TSAb","volume":"78","author":"Ochi","year":"2012","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2019.03.030_b0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/1871530313666131224115000","article-title":"Conversion of TBAb response to TSAb response by anti-human IgG antibody","volume":"13","author":"Ochi","year":"2013","journal-title":"Endocrine Metab Immune Disorders Drug Targets"},{"key":"10.1016\/j.mehy.2019.03.030_b0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1871530315666150824154909","article-title":"A novel method for measuring TBAb activity in TSAb- and TBAb- positive serum","volume":"15","author":"Ochi","year":"2015","journal-title":"Endocrine Metab Immune Disorders Drug Targets"},{"key":"10.1016\/j.mehy.2019.03.030_b0020","first-page":"395","article-title":"Specific effects of radioiodine administration","volume":"17","author":"Michelangeli","year":"1982","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.mehy.2019.03.030_b0025","first-page":"40","article-title":"Outcome of thyroid function in graves\u2019 patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage","volume":"83","author":"Chiovato","year":"1998","journal-title":"J Cline Endocrinol Metab"},{"key":"10.1016\/j.mehy.2019.03.030_b0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1089\/thy.2000.10.909","article-title":"Characterization of thyroid stimulating blocking antibodies that appeared during transient hypothyroidism after radioactive iodine therapy","volume":"10","author":"Kung","year":"2000","journal-title":"Thyroid"},{"key":"10.1016\/j.mehy.2019.03.030_b0035","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1210\/jcem-62-2-368","article-title":"Prediction and therapy of intrauterine and late-onset neonatal hyperthyroidism","volume":"62","author":"Zakarija","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.mehy.2019.03.030_b0040","first-page":"307","article-title":"Fluorescent antibody studies in human thyroiditis: auto-antibodies to an antigen of the thyroid colloid distinct from thyroglobulin","volume":"42","author":"Balfour","year":"1961","journal-title":"Br J Exp Pathol"},{"key":"10.1016\/j.mehy.2019.03.030_b0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.0954-6820.1963.tb07905.x","article-title":"The occurrence of antibody against \u201cSecond colloid Antigen\u201d (CA-2 Antibody) in patients with and without thyroid disease","volume":"174","author":"Hjort","year":"1963","journal-title":"Acta Medica Scandinavica"},{"key":"10.1016\/j.mehy.2019.03.030_b0050","first-page":"659","article-title":"Antibodies to second colloid antigen; A study on the prevalence in sporadic forms of congenital hypothyroidism","volume":"121","author":"van Trotsenburg","year":"1989","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.mehy.2019.03.030_b0055","first-page":"1","article-title":"Studies on a human thyroid protease","volume":"21","author":"Shapland","year":"1964","journal-title":"J Med Lab Technol"},{"key":"10.1016\/j.mehy.2019.03.030_b0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1507\/endocrj1954.34.237","article-title":"Disappearance of blocking type thyrotropin binding inhibitor immunoglobulin (TBII) during thyroid and steroid medication in a patient with autoimmune thyroiditis","volume":"34","author":"Mori","year":"1987","journal-title":"Endocrinol Jpn"},{"key":"10.1016\/j.mehy.2019.03.030_b0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF03350693","article-title":"Disappearance of thyroid-stimulation blocking antibody by glucocorticoid therapy in a patient with primary myxedema who developed aortitis syndrome during L-thyroxine supplementation","volume":"13","author":"Shigemasa","year":"1990","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.mehy.2019.03.030_b0070","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.2727702","article-title":"Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody","volume":"244","author":"Paul","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.mehy.2019.03.030_b0075","article-title":"DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia","volume":"9","author":"Emakov","year":"2015","journal-title":"Open Biol"},{"key":"10.1016\/j.mehy.2019.03.030_b0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0009-8981(84)90349-8","article-title":"Immunochemical identification of an \u03b11-acid glycoprotein-antigenic determinant on carcinoembryonic antigen (CEA) and non-specific cross-reacting antigen (NCA)","volume":"138","author":"Ochi","year":"1984","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.mehy.2019.03.030_b0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0006-291X(87)90304-4","article-title":"Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sezuence","volume":"142","author":"Oikawa","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.mehy.2019.03.030_b0090","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0006-291X(87)80013-X","article-title":"The carcinoembryonic antigen (CEA) contains multiple immunoglobulin-like domains","volume":"144","author":"Oikawa","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.mehy.2019.03.030_b0095","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1073\/pnas.84.4.920","article-title":"Sequence analysis of carcinoembryonic antigen: identification of glycosylation sites and homology with the immunoglobulin supergene family","volume":"84","author":"Paxton","year":"1987","journal-title":"PNAS"},{"key":"10.1016\/j.mehy.2019.03.030_b0100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1081\/IAS-120015477","article-title":"Sensitive thyroid stimulating antibody (TSAb) assay using polyethylene glycol (PEG) \u2013 a review","volume":"23","author":"Ochi","year":"2002","journal-title":"J Immunoassay Immunochem"},{"key":"10.1016\/j.mehy.2019.03.030_b0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0065-2776(08)60847-0","article-title":"Myasthenia graves","volume":"42","author":"Lindstrom","year":"1988","journal-title":"Adv Immunol"},{"key":"10.1016\/j.mehy.2019.03.030_b0110","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/0161-5890(92)90224-L","article-title":"Human anti-acetylcholine receptor antibodies use variable gene segments analogous to the those used in autoantibodies of various specificities","volume":"29","author":"Victor","year":"1992","journal-title":"Mol Immunol"},{"key":"10.1016\/j.mehy.2019.03.030_b0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/jcem-48-1-59","article-title":"Immunoprecipitation of the insulin receptor: a sensitive assay for receptor antibodies and a specific technique for receptor purification","volume":"48","author":"Harrison","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.mehy.2019.03.030_b0120","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1210\/jc.2006-2213","article-title":"Stimulating and blocking thyroid stimulating hormone (TSH) receptor autoantibodies from patients with Graves\u2019 disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity and binding sites","volume":"92","author":"Morgenthaler","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.mehy.2019.03.030_b0125","first-page":"423","article-title":"Caracteristics of auto-antibodies to bovine TSH in the serum of two patients with Graves\u2019 disease","volume":"104","author":"Kajita","year":"1983","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.mehy.2019.03.030_b0130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2174\/1871530318666180220101845","article-title":"Antithyroid drugs inactivate TSH binding to the TSH receptor by their reducing action","volume":"18","author":"Ochi","year":"2018","journal-title":"Endocrine Metab Immune Disorders Drug Targets"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718312891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718312891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:14:52Z","timestamp":1759691692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987718312891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":26,"alternative-id":["S0306987718312891"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.03.030","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible participation of colloid antigen 2 and abhormone (IgG with hormone activity) for the etiology of Graves\u2019 disease","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}